Alzheimer’s Drug Trials Plagued by Lack of Racial Diversity

Under-representation of people of color sparks concerns over the safety and efficacy of drugs in diverse populations. Black and Hispanic people are up to twice as likely as white people to develop Alzheimer’s disease, but they have a much lower chance of being included in clinical trials for Alzheimer’s treatments.